Everest Medicines
Dr. Yang has two decades of leadership experience in drug discovery and development at global pharmaceutical companies. Prior to joining Everest, Dr. Yang served as vice president and head of China for Johnson & Johnson’s Lung Cancer Initiative where she established and led a cross-sector research and development (R&D) organization for the creation of innovative solutions for lung cancer prevention, interception, and cure. Jennifer transitioned into this role from Janssen (China) Research & Development Center, where she was the head of the Discovery Center. Prior to joining Johnson and Johnson, Dr. Yang held global leadership positions at Eli Lilly and Company and Pfizer Inc Oncology Research Unit in the United States.
Dr. Yang holds a Ph.D. in molecular biology and human genetics from the Eccles Institute of Human Genetics at the University of Utah, a Master’s degree in immunology and microbiology from Southern Illinois University, and a Bachelor of Science degree in microbiology from Fudan University in China.
This person is not in any offices
Everest Medicines
Everest Medicines is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies with the mission of addressing critical unmet medical needs in Greater China and other emerging Asia Pacific markets.